Patient‑Level KRAS G12C Prevalence among Hispanic/Latino and Non‑Hispanic White Patients in Real‑world Clinicogenomic Cohorts
KRAS G12C prevalence was lower in Hispanic/Latino patients compared with non‑Hispanic White patients in lung adenocarcinoma (MSK‑CHORD: 7.9 % vs. 15.4 %; GENIE: 7.2 % vs. 15.1 %).
KRAS G12C is a clinically actionable oncogenic alteration that defines treatment options in non‑small cell lung cancer (NSCLC), particularly lung adenocarcinoma. This retrospective study compared patient‑level KRAS G12C prevalence between Hispanic/Latino (H/L) and non‑Hispanic White (NH‑W) patients using two real‑world clinicogenomic databases (MSK‑CHORD and AACR GENIE). In lung adenocarcinoma, KRAS G12C prevalence was significantly lower in H/L patients than in NH‑W patients (MSK‑CHORD: 7.9 % vs. 15.4 %; OR = 0.47, 95 % CI 0.30–0.74; GENIE: 7.2 % vs. 15.1 %; OR = 0.44, 95 % CI 0.33–0.58). The difference was much smaller and not statistically significant in non‑lung‑adenocarcinoma NSCLC. Adjustment for smoking status reduced the odds ratio toward the null, suggesting smoking as a key confounder. These findings underscore a histology‑specific, population‑aware disparity in KRAS G12C burden in lung adenocarcinoma.
KRAS G12C is a direct therapeutic target; understanding its prevalence in diverse ethnic groups informs screening strategies, eligibility for targeted therapies, and trial recruitment.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT